Comprehensive Atopic Dermatitis Care: Enhancing Patient Care through Collaborative Management

Led by a nationally renowned faculty team of dermatology experts this curriculum will highlight various aspects of a multidimensional, holistic approach for better patient management by primary care and dermatology providers. This expert faculty discussion will include the recent advances in the AD treatment landscape, evidence-based recommendations for care, including behavioral modifications or habit reversal techniques for itch, and the importance of care coordination strategies with specialty providers. Additionally, woven throughout the curriculum, we will introduce brief, specific cases with video vignettes of actual patients with AD. The patients will speak about the challenges they face concerning the ongoing treatment and management of their condition, with a particular focus on quality of life issues.

 

Target Audience

Dermatologists, Family Practitioners, Primary Care Providers, Pediatricians, Nurses, Nurse Practitioners, and Physician Assistants

 

Learning Objectives

At the conclusion of this activity, participants will be able to (or better able to):

  1. Review strategies to overcome AD knowledge and management gaps (e.g., identification, prevention, reducing disease burden)
  2. Assess current pharmacologic and non-pharmacologic options for the treatment of AD.
  3. Discuss strategies for coordination of care with specialists based on evidence-based standards
  4. Review the quality of life burden of AD (e.g., emotional/psychosocial, sleep disturbance, decreased productivity)
  5. Utilizing video vignettes of actual patients, recognize the quality of life burdens with AD including factors such as emotional and psychosocial effects, sleep disturbances, and decreased attention span and productivity.
Course summary
Available credit: 
  • 1.25 AAP
    This continuing medical education activity has been reviewed by the American Academy of Pediatrics and is acceptable for a maximum of 1.25 AAP credits. These credits can be applied toward the AAP CME/CPD Award available to Fellows and Candidate Members of the American Academy of Pediatrics.
  • 1.25 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 ANCC
  • 1.25 Participation
Course opens: 
09/30/2020
Course expires: 
09/30/2021

 

 

Travel

Eu sem integer vitae justo eget magna fermentum.

FACULTY

Margaret S. Lee, MD, PhD
Course Director
Assistant Professor of Dermatology and Pediatrics
Director of Pediatric Dermatology
Boston University School of Medicine
Pediatric Dermatologist
Boston Medical Center
Boston, MA

Dr. Lee receives research support from Pfizer Inc.

Peter Lio, MD
Clinical Assistant Professor of Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Medical Dermatology Associates of Chicago, LTD
Chicago, IL

Dr. Lio is on the advisory board for Arbonne, Johnson and Johnson, Derm Tap, Inc., Intraderm Pharmaceuticals, Regeneron, Sanofi US Services, Realm Therapeutics, Menlo Therapeutics, Modernizing Medicine, Syncere Skin Systems, DermVeda, gpower inc., UCB, Altus Labs, Dermavant Sciences, Micreos Human Health B.V., and Verrica Pharmaceuticals Inc.; is a speaker for Regeneron and La Roche-Posay Laboratorie Pharmaceutique.; is a consultant for Exeltis, Theraplex, Odeza LLC, L'Oreal USA Inc., Franklin BioScience, AbbVie, Kiniksa Pharmaceuticals, Ltd, Eli Lilly and Company, Unilever, Dermira TopMD, Amyris, Inc., and LEO Laboratories Ltd . Dr. Lio is also a stockholder for Derm Tap, Inc., LearnHealth/LearnSkin, Modernizing Medicine, Pfizer Inc. and Pierre Fabre Dermatologie and also receives patent royalties from Theraplex.

Elaine C. Siegfried, MD 
Professor of Pediatrics and Dermatology
Director, Division of Pediatric Dermatology
Saint Louis University and Cardinal Glennon Children’s Hospital
St. Louis, MO

Dr. Siegfried is a consultant for Abbvie, Dermavant Sciences, GlaxoSmithKline, Novan, Pierre Fabre Dermo- Cosmétique, Pfizer Inc., LEO Pharma, Regeneron, Sanofi, UCB, Valeant Pharmaceuticals, Verrica Pharmaceuticals; is a principal investigator for Allergan Inc., Amgen, Eli Lilly, Janssen Pharmaceuticals Inc., Mayne Pharma Group, Medimetriks Pharmaceuticals, Inc., Pfizer Inc., Pierre Fabre Dermo-Cosmétique US, Regeneron, Verrica Pharmaceuticals, and Janssen Pharmaceuticals Inc.; is on the data safety management board for Novan, Pfizer Inc., and LEO Pharma.; and is on the advisory board for Verrica Pharmaceuticals.

CME Project Manager: Michael Burk

CME Accreditation

Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Boston University School of Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NCPD Accreditation

Boston University School of Medicine Continuing Nursing Education Provider Unit is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Contact Hours: 1.25, of which 0.50(30 minutes) is eligible for pharmacology credit

AAFP Prescribed Credit

This Enduring Material activity, Comprehensive Atopic Dermatitis Care: Enhancing Patient Care through Collaborative Management, has been reviewed and is acceptable for credit by the American Academy of Family Physicians. Term of approval begins 09/30/2020. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

1.25 Enduring Materials, Self-Study AAFP Prescribed credit

AAP Credits

This continuing medical education activity has been reviewed by the American Academy of Pediatrics and is acceptable for a maximum of 1.25 AAP credits. These credits can be applied toward the AAP CME/CPD Award available to Fellows and Candidate Members of the American Academy of Pediatrics.

This activity is acceptable for a maximum of 1.25 AAP credits.

 

Available Credit

  • 1.25 AAP
    This continuing medical education activity has been reviewed by the American Academy of Pediatrics and is acceptable for a maximum of 1.25 AAP credits. These credits can be applied toward the AAP CME/CPD Award available to Fellows and Candidate Members of the American Academy of Pediatrics.
  • 1.25 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 ANCC
  • 1.25 Participation
Virtual Exhibitor Hall

 

Please login or register to take this course.

Cancellation Policy

Feugiat pretium nibh ipsum consequat nisl vel pretium lectus. Vehicula ipsum a arcu cursus vitae congue mauris rhoncus. Morbi leo urna molestie at elementum. Eget duis at tellus at. Molestie at elementum eu facilisis sed odio morbi quis. Egestas congue quisque egestas diam in arcu cursus euismod. Nunc scelerisque viverra mauris in aliquam sem fringilla ut. Sagittis nisl rhoncus mattis rhoncus urna neque. Viverra maecenas accumsan lacus vel. Purus in massa tempor nec feugiat nisl pretium fusce. Facilisi morbi tempus iaculis urna id. In vitae turpis massa sed elementum. Non tellus orci ac auctor augue mauris augue neque gravida. Diam sit amet nisl suscipit adipiscing bibendum est. Enim sit amet venenatis urna cursus. Velit ut tortor pretium viverra suspendisse potenti. Aliquam ultrices sagittis orci a scelerisque purus semper eget. Nisl purus in mollis nunc sed id. Turpis nunc eget lorem dolor sed viverra ipsum nunc.

 

Refund Policy 

Lobortis feugiat vivamus at augue. Id velit ut tortor pretium viverra suspendisse potenti nullam ac. Netus et malesuada fames ac turpis egestas integer eget. Augue ut lectus arcu bibendum at varius vel. Mattis molestie a iaculis at erat pellentesque adipiscing. Vitae semper quis lectus nulla at volutpat diam. Et malesuada fames ac turpis. Eu non diam phasellus vestibulum. Pellentesque elit ullamcorper dignissim cras tincidunt lobortis feugiat. Ligula ullamcorper malesuada proin libero nunc consequat interdum varius. Congue mauris rhoncus aenean vel. Imperdiet dui accumsan sit amet nulla facilisi morbi tempus iaculis. Ultrices vitae auctor eu augue. Egestas maecenas pharetra convallis posuere morbi leo. Faucibus et molestie ac feugiat sed lectus vestibulum. Viverra nam libero justo laoreet sit amet cursus sit. Justo donec enim diam vulputate ut pharetra sit amet.